PPBT
Purple Biotech Ltd. NASDAQ Listed Nov 20, 2015$1.70
Mkt Cap $234.7K
52w Low $1.42
1.0% of range
52w High $29.00
50d MA $3.05
200d MA $5.35
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
0.0x
ROE
—
P/FCF
-0.0x
RSI (14)
60.30
ATR (14)
$0.16
Beta
-0.70
50d MA
$3.05
200d MA
$5.35
Avg Volume
623.1K
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
4 Oppenheimer Street · Rehovot, L3 7670104 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | AMC | -3.40 | -19.85 | -483.8% | 4.10 | -0.7% | -0.2% | -2.4% | -4.5% | -0.5% | +5.0% | — |
| Nov 14, 2025 | AMC | -0.26 | -0.29 | -11.5% | 7.18 | -1.5% | +0.3% | +11.2% | -4.6% | -0.3% | +0.5% | — |
| Aug 6, 2025 | AMC | -0.21 | -0.40 | -90.5% | 21.50 | -0.9% | +0.0% | -0.9% | +3.3% | +2.3% | -0.9% | — |
| May 21, 2025 | AMC | — | -0.17 | — | 23.70 | +3.8% | +5.1% | -3.7% | -2.2% | +4.5% | -2.4% | — |
| Mar 10, 2025 | AMC | -0.22 | -0.26 | -18.2% | 27.15 | +1.7% | -2.4% | +3.0% | -1.1% | +0.9% | +2.8% | — |
| Nov 15, 2024 | AMC | -1.20 | -1.37 | -14.2% | 25.05 | +0.6% | +1.8% | +2.7% | -5.7% | +2.8% | -13.8% | — |
| Aug 16, 2024 | AMC | -0.16 | -1.60 | -900.0% | 73.44 | +0.7% | +0.2% | +14.2% | -5.3% | -4.5% | +5.2% | — |
| May 21, 2024 | AMC | -3.00 | -3.00 | +0.0% | 120.00 | +3.5% | +13.3% | +17.6% | -6.9% | +5.4% | -0.6% | — |
| Mar 5, 2024 | AMC | -3.40 | -6.40 | -88.2% | 160.00 | +3.8% | +1.9% | +6.2% | -5.2% | -6.5% | -4.1% | — |
| Nov 21, 2023 | AMC | -4.40 | -4.20 | +4.5% | 198.50 | +0.8% | +2.8% | +1.0% | -4.9% | +1.0% | +9.1% | — |
| Aug 22, 2023 | AMC | -5.00 | -4.60 | +8.0% | 246.00 | -1.6% | -2.4% | -2.5% | +0.0% | -0.4% | +3.0% | — |
| May 16, 2023 | AMC | -7.00 | -4.20 | +40.0% | 366.00 | +1.6% | +3.0% | -1.3% | +3.2% | +2.1% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.84 | $3.83 | -0.3% | +6.8% | -0.2% | -2.4% | -4.5% | -0.5% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.20 | $25.10 | -0.4% | -0.6% | +1.8% | +2.7% | -5.7% | +2.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.80 | $70.30 | +0.7% | -1.3% | -5.8% | -7.5% | -5.9% | -8.4% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.44 | $73.98 | +0.7% | +0.2% | +14.2% | -5.3% | -4.5% | +5.2% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $82.56 | $81.30 | -1.5% | -7.8% | +4.9% | -4.8% | -0.4% | +1.0% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $112.63 | $116.60 | +3.5% | +6.5% | +13.3% | +17.6% | -6.9% | +5.4% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $103.20 | $98.00 | -5.0% | -5.0% | +4.1% | +1.7% | +0.8% | +3.4% |
| Mar 7 | Chardan Capital | Maintains | Buy → Buy | — | $163.00 | $167.50 | +2.8% | +6.2% | -5.2% | -6.5% | -4.1% | -3.4% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $166.00 | $158.40 | -4.6% | -3.6% | +1.9% | +6.2% | -5.2% | -6.5% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $142.54 | $146.80 | +3.0% | -5.9% | +4.3% | +17.4% | +11.8% | -9.6% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $200.00 | $193.82 | -3.1% | -0.8% | +2.8% | +1.0% | -4.9% | +1.0% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $240.00 | $244.00 | +1.7% | +0.8% | +7.4% | -3.1% | -3.2% | -2.5% |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $240.00 | $236.00 | -1.7% | +0.0% | +0.8% | +7.4% | -3.1% | -3.2% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $366.00 | $372.00 | +1.6% | +3.0% | -1.3% | +3.2% | +2.1% | -0.5% |
| May 17 | Chardan Capital | Maintains | Buy → Buy | — | $366.00 | $372.00 | +1.6% | +3.0% | -1.3% | +3.2% | +2.1% | -0.5% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $369.00 | $360.00 | -2.4% | +1.9% | -1.6% | +1.1% | +6.7% | +12.8% |
| Feb 9 | Chardan Capital | Maintains | Buy → Buy | — | $369.00 | $360.00 | -2.4% | +1.9% | -1.6% | +1.1% | +6.7% | +12.8% |
| Oct 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $396.00 | $430.00 | +8.6% | -1.5% | +3.8% | +0.7% | +1.0% | +2.4% |
| Sep 8 | Chardan Capital | Maintains | Buy → Buy | — | $454.00 | $500.00 | +10.1% | -5.3% | +0.0% | +6.0% | -3.1% | -0.5% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 7
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Susquehanna International Group, Llp | 53,403 | $216K | New | Mar 2026 |
| 2 | Bnp Paribas Financial Markets | 1,957 | $8K | New | Mar 2026 |
| 3 | Simplex Trading, Llc | 597 | $2K | New | Mar 2026 |
| 4 | Gamma Investing Llc | 108 | $436 | New | Mar 2026 |
| 5 | Ubs Group Ag | 99 | $400 | New | Mar 2026 |
| 6 | Danske Bank A/s | 4 | $16 | New | Mar 2026 |
| 7 | Royal Bank Of Canada | 10 | — | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$235K
Enterprise Value
-$9.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.00x
P/S
—
P/FCF
-0.00x
EV/EBITDA
—
Shares Out
2K
Financials (TTM)
Revenue
$0
Net Income
-$26.2M
EBITDA
-$5.2M
Free Cash Flow
-$5.5M
Op Cash Flow
-$5.5M
EPS Basic
$-11080.00
EPS Diluted
$-9933.94
EPS Forward
$-1.65
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$17.6M
Total Liab.
$7.9M
Total Equity
$9.7M
Cash
$9.6M
LT Debt
$0
Book Value/Sh
$4024.08
Debt/Equity
0.03x
Current Ratio
1.27
Quick Ratio
1.27
Returns & Growth
ROE
—
ROA
—
ROIC
-69.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
-24967.9%
Price Returns
2W
-3.4%
1M
-42.4%
3M
-58.9%
6M
-74.2%
12M
-93.1%
Technicals
52W High
$29.00
52W Low
$1.42
50d MA
$3.05
200d MA
$5.35
RSI (14)
60.30
ATR (14)
$0.16
Beta
-0.70
Avg Volume
623K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 8:27pm
· Source: financialmodelingprep.com